(A Phase 2) STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (Rd) FOLLOWED BY RITUXIMAB, AUTOGRAFT AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED WALDESTROM MACROGLOBULINEMIA SUBJECTS

Trial Profile

(A Phase 2) STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (Rd) FOLLOWED BY RITUXIMAB, AUTOGRAFT AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED WALDESTROM MACROGLOBULINEMIA SUBJECTS

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2013

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone; Rituximab
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 12 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top